The MHRA is the organisation that regulates licensing of new drugs in the UK. They took over from the EMA (European Medicines Agency) since Brexit. They are now proposing to […]

The office and the helpline will be closed from Saturday 24th December 2022 to Monday 2nd January 2023 inclusive. We will be re-opening on Tuesday 3rd January 2023. Our Facebook page and Chat Forum will remain open for any member to member communication. For any clinical queries, as ever, please contact your clinical team. Wishing you all a restful, safe, healthy festive break. We will be here to answer calls or emails until 5.30pm on 23rd December 2022.

Please note we will be closed during the festive season from Monday 27th December to Tuesday 4th January 2022. Have a look at our Top Tips: Having MDS has impact […]

Just a little reminder for you to let your hair down and come along to the Christmas Zoom café social tomorrow!
When: Tuesday 13th December
Time: 1.30pm-3pm
Where: Online via Zoom
Please register as soon as you can so we can plan the activities but, in advance, here are some handy hints for attending…

Create a dedication for someone special this Christmas to show you are thinking of them. Your robin symbolises hope and happiness.
While there’s no obligation to donate when creating a dedication, it is easy to do and we would truly appreciate it. Simply, click on the tree, choose a robin of your choice and make a donation. All money raised will help MDS UK to support those living with the condition in the UK.

Blood cancer patients are less likely to see their needs fully met than patients with the four most common cancers – breast, colorectal, lung and prostate. The blood cancer community, […]

This article was first published on the MDS Foundation Fall/Winter 2021 Newsletter. Many thanks to our colleagues from the MDS Foundation. Important: The article below is destined to an American […]

To better understand and raise awareness of your needs, the MDS Alliance has designed the MDS Global Survey. The survey includes a validated quality of life tool (QUALMS) and is […]

Deferasirox is only licensed second line for the treatment of chronic iron overload despite real-world experience showing that deferasirox is better tolerated and its compliance is far superior than first […]

The UK’s blood cancer patient community are clinically extremely vulnerable to COVID-19. Several studies showed that about 60% of blood cancer patients failed to develop effective antibodies for an immune […]